98%
921
2 minutes
20
Introduction: Some living organ donors will decide to donate again at a later date. Evidence has indicated that this practice may have increased in recent years. We evaluated the incidence and outcomes of this practice to inform counseling of potential repeat donors.
Methods: Using SRTR data from 1994 to 2023, we identified 220 repeat living donors and their 415 recipients. We constructed donor comparison groups using weighting by the odds. We described clinical and lab results at 6 months, 1 year, and 2 years post-donation separately for kidney-second donors and liver-second donors. We compared all-cause graft failure for their recipients with those of comparison donors.
Results: The annual count of repeat living donors increased from 5 in 2018 to 25 in 2019 (p < 0.001). Of 220 donors, 159 were liver-second donors (72.3%) and 55 were kidney-second donors (25.0). The percentage of nondirected donations increased from 30.5% at first donation to 53.2% at second donation (p < 0.001). Liver-second donors had one death approximately 2.5 years post-donation. Seventeen were re-admitted and 20 experienced complications requiring an interventional procedure or re-operation. Among kidney-second donors, no deaths, re-admissions, or post-donation complications were reported. Post-donation outcomes in both groups were comparable when evaluated against organ-specific comparison donors. Recipients of repeat living donors experienced graft survival similar to recipients of comparison donors.
Conclusions: Repeat living donation may be a safe practice for carefully selected living donors in the short term; however, long term safety is unknown. Outcomes for recipients are similar to recipients of comparison donors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ctr.70049 | DOI Listing |
Hematology
December 2025
Adult Hematology, Transplantation and Cellular Therapy Section, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Objectives: To describe a rare case of transplantation-mediated alloimmune thrombocytopenia (TMAT) following liver transplantation from a donor with immune thrombocytopenia (ITP), and to contextualize findings within the literature.
Methods: We reviewed the clinical course of a 63-year-old man with hepatitis C cirrhosis and hepatocellular carcinoma who underwent orthotopic liver transplantation from a donor with severe thrombocytopenia consistent with ITP. Clinical, laboratory, and bone marrow findings were analyzed, and alternative causes of thrombocytopenia were excluded.
JTCVS Open
August 2025
Department of Cardiothoracic Surgery, University of Louisville and Norton Children's Hospital, Louisville, Ky.
Objectives: Severe obesity is an established risk factor for adverse cardiovascular events and heart transplantation (HT) outcomes in adults. However, the effect of severe obesity on children after HT is not well studied. We aimed to examine the prevalence and effect of severe obesity on pediatric HT.
View Article and Find Full Text PDFArch Esp Urol
August 2025
Urology Department, Hospital and University Complex of Albacete, 02006 Albacete, Spain.
Background: Delayed graft function is a common situation that leads to increased long-term rates of graft rejection and loss. It is seen increasingly more often, as the use of kidneys from donors after controlled cardiac death has become more widespread. This study aimed to identify factors contributing to its onset and determine how these factors may influence graft survival.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Department of Emergency Medicine, Ajou University School of Medicine, Suwon, South Korea.
This study aimed to investigate the clinical course of brain death donors and admitted through the emergency department before organ procurement and early outcomes of kidney transplantation. We retrospectively reviewed the medical records of patients who visited a single tertiary emergency department with the final diagnosis of brain death and donor procurement between January 2013 and January 2022. Donors were categorized into 3 groups: brain hemorrhage, hanging, and other medical causes.
View Article and Find Full Text PDFTranspl Immunol
September 2025
Intensive Care, Royal Free Hospital, Hampstead, London, United Kingdom.
Background: Inflammatory injury in organ donors, particularly after brain death and during ischemia-reperfusion, contributes to graft dysfunction, rejection, and reduced survival. Statins, beyond their lipid-lowering role, exert pleiotropic anti-inflammatory and immunomodulatory effects, including IL-6 suppression, NF-κB inhibition, immune cell modulation, and potential alteration of exosome secretion.
Methods: Building upon this background, this narrative review synthesises preclinical and clinical evidence on pre-donation statin therapy in solid organ transplantation.